GlycoMark
GlycoMark Updates for Healthcare Professionals Caring for Patients with Diabetes
DIABETES MANAGEMENT Issue 13 - November 2018
Dear Clinician,

November is National Diabetes Month and an ideal opportunity to try new methods to enhance the management of patients with diabetes.

The GlycoMark test is one of those methods. Here’s why:
The GlycoMark test:
Complements A1C and provides shorter-term visibility to glucose variability and excursions that sporadic blood glucose and quarterly A1C cannot detect.
Helps identify patients that would benefit from closer management, including ...
Learn More
To Learn More, visit www.GlycoMark.com
1. Experience our NEW online video and chat system with clinical experts, available weekdays, 9 a.m. to 5 p.m. ET. You may also schedule a call-back when convenient for YOU.
2. Explore NEW educational tools, clinical perspectives, case studies and resources.
To Try the Test
Try 10 GlycoMark tests! During National Diabetes Month, GlycoMark will provide complimentary follow up by a GlcyoMark Specialist to help review, interpret test results, and answer your questions, one-on-one!
Learn More
How to Order the GlycoMark Test:
The GlycoMark test is reimbursed by federal, state and private payers (CPT Code 84378) and available through various national and regional laboratories, and as a test kit for use on most automated chemistry instruments. Click Here for more information!
1. Erlinger TP, Brancati FL. Diabetes Care. 2001 Oct;24(10):1734-8.
2. Bonora E, et al. Diabetologia. 2006 May;49(5):846-54.

The Mark newsletter is distributed to healthcare professionals that treat and manage patients with diabetes, and contains the latest updates and important references for the GlycoMark test. This is a complimentary publication provided through the generous support of GlycoMark, Inc.

The information contained herein is not medical, diagnostic or treatment advice for any particular patient. Physicians should use their clinical judgment and experience when deciding how to diagnose and treat patients and in the use of the GlycoMark test in the treatment of the patient. Please refer to the GlycoMark product insert for more information.

The GlycoMark test is FDA cleared for professional use to provide quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The GlycoMark test is intended for intermediate-term monitoring of glycemic control in patients with diabetes. It is not intended to be used to identify patients that will experience complications of diabetes or the likelihood of experiencing complications.

GlycoMark, Inc. is the exclusive licensee of the GlycoMark test, trademark and logo. © 2018 GlycoMark, Inc. All Rights Reserved. M-70-1A
GlycoMark
805 Third Avenue, 17th Floor, New York, NY 10022
1-888-744-0221 - info@glycomark.com - www.glycomark.com